Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aceragen, Inc.IDRA · Entity 110652 | Chief Financial Officer | August 13, 2018 | August 15, 2018 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director · President and CEO | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aceragen, Inc.
Report date August 13, 2018 · Filed August 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.39 · Expires 2028-08-13 | Direct | 32,500 |
Reported balance
After 2018-08-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-08-13 · Grant · Acquired 32,500 · Balance 32,500 F1: This option was granted under the Company's 2013 Stock Incentive Plan. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted under the Company's 2013 Stock Incentive Plan. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant.
Tempest Therapeutics, Inc.
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.06 · Expires 2031-02-25 | Direct | 400,000 |
Reported balance
After 2021-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-26 · Grant · Acquired 400,000 · Balance 400,000 F1: 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2021 Filed Mar 2, 2021 17:18 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 400,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001544227-21-000010 · wf-form4_161472344947814.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: 1. Twenty-five percent (25%) of the shares subject to this option shall vest on February 1, 2022, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. However, all such options, to the extent outstanding immediately prior to a Change in Control (as defined in the 2019 Equity Incentive Plan), will be (or will be deemed to have been) fully vested and exercisable as of immediately prior to such Change in Control. Read SEC document |
| May 25, 2020 Filed May 27, 2020 21:45 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001209191-20-032489 · doc4.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-05-24 F1 · derivative.exercise_date: Fifty percent (50%) of the shares subject to this option shall vest on the earlier of: (i) December 31, 2020 or (ii) the Board's approval of the achievement of certain performance criteria, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:29 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 71,250 | $0.00 Strike: $7.94 | $0.00 |
DisclosureSEC source: 0001209191-20-006345 · doc4.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires 2030-01-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 7, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 16:33 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-038475 · doc4.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 16:43 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004226 · doc4.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option shall vest on January 15, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| December 07, 2018 Filed Dec 11, 2018 19:35 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantEmployee Stock Option (right to buy) · Derivative | 74,400 | $0.00 Strike: $10.40 | $0.00 |
DisclosureSEC source: 0001209191-18-062105 · doc4.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,400 Underlying: Common Stock · 74,400 shares Expires 2028-12-06 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest on November 1, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 16:32 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 32,500 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001104659-18-052291 · a4.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2028-08-13 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The option vests with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 16:20 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 270,000 | $2.24 Strike: $2.24 | $604,800.00 |
DisclosureSEC source: 0001179110-18-000587 · edgar.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 16:24 UTC | Aceragen, Inc. IDRA · Entity 110652 | GrantStock Option · Derivative | 185,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001179110-17-000646 · edgar.xml · derivative · entry 1 Arcudi III Louis J · CIK 0001419350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,000 Underlying: Common Stock · 185,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: This option was granted under the Company's 2013 Stock Incentive Plan. The options vest with respect to 25% of the underlying shares on the first anniversary of the date of grant and the balance of the underlying shares vest in twelve equal quarterly installments following the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.